Einrichtungen, die zum Universitätsklinikum Erlangen gehören

Stromal cells enhance PD-L1 expression on CLL cells via the oncogenic Notch-cMyc-EZH2 signaling axis (2020) Böttcher M, Mentz K, Popp S, Saul D, Bruns H, Mackensen A, Mougiakakos D, Völkl S Conference contribution N-glycosylation controls inflammatory licensing-triggered PD-L1 upregulation in human mesenchymal stromal cells (2020) Strauch V, Saul D, Mackensen A, Jitschin R, Mougiakakos D Conference contribution Immunometabolic alterations in lymphoma patients with early relapse upon autologous stem cell transplantation (2020) Richter S, Jacobs B, Mackensen A, Mougiakakos D, Völkl S Conference contribution Low-dose interleukin-2 for the treatment of glucocorticoid-refractory acute graft-versus-host disease: a single center experience (2020) Brandt A, Vasova I, Winkler J, Mackensen A, Rösler W, Spoerl S, Völkl S Conference contribution Profiling extracellular vesicles (EV) in patients with acute GvHD after allogeneic stem cell transplantation (2020) Böttcher M, Stoll A, Böttcher-Loschinski R, Rösler W, Winkler J, Mackensen A, Mougiakakos D, et al. Conference contribution Fever of unknown origin following allogeneic stem cell transplantation - an unusual case (2020) Meintker L, Kremer A, Brandt A, Spoerl S, Slanikova A, Mackensen A, Winkler J, Rösler W Conference contribution CD19 CAR-T cell treatment of CNS relapse of Burkitt's lymphoma: A case report (2020) Aigner M, Jacobs B, Gary R, Kretschmann S, Achenbach S, Mackensen A, Mougiakakos D, et al. Conference contribution 4-1BB/CD137 triggering on human monocytes leads to differentiation into macrophages with increased metabolic support and tumoricidal capacity (2020) Stoll A, Bruns H, Gamali S, Saul D, Mackensen A, Mougiakakos D Conference contribution Impact of Nrf2 expression in reconstituting T-cells of allogeneic hematopoietic stem cell transplanted patients (2020) Karl F, Stoll A, Gamali S, Böttcher-Loschinski R, Böttcher M, Baur R, Jacobs B, et al. Conference contribution Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8 (2020) Hecht M, Gostian AO, Eckstein M, Rutzner S, von der Grün J, Illmer T, Hautmann MG, et al. Journal article